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ABSTRACT
Background Many Americans with metastasised
colon cancer do not receive indicated palliative
chemotherapy. We examined the effects of
health insurance and physician supplies on such
chemotherapy in California.
Methods We analysed registry data for 1199
people with metastasised colon cancer
diagnosed between 1996 and 2000 and
followed for 1 year. We obtained data on health
insurance, census tract-based socioeconomic
status and county-level physician supplies. Poor
neighbourhoods were oversampled and the
criterion was receipt of chemotherapy. Effects
were described with rate ratios (RR) and tested
with logistic regression models.
Results Palliative chemotherapy was received by
less than half of the participants (45%).
Facilitating effects of primary care (RR=1.23) and
health insurance (RR=1.14) as well as an
impeding effect of specialised care (RR=0.86)
were observed. Primary care physician (PCP)
supply took precedence. Adjusting for poverty,
PCP supply was the only significant and strong
predictor of chemotherapy (OR=1.62, 95% CI
1.02 to 2.56). The threshold for this primary care
advantage was realised in communities with 8.5
or more PCPs per 10 000 inhabitants. Only 10%
of participants lived in such well-supplied
communities.
Conclusions This study’s observations of
facilitating effects of primary care and health
insurance on palliative chemotherapy for
metastasised colon cancer clearly suggested a
way to maximise Affordable Care Act (ACA)
protections. Strengthening America’s system of
primary care will probably be the best way to
ensure that the ACA’s full benefits are realised.
Such would go a long way towards facilitating
access to palliative care.
BACKGROUND
Colon cancer is the second leading cause
of cancer death in the USA, but its
prognosis can be excellent with early
diagnosis and expeditious access to
evidence-based treatments.1 2 Regrettably,
though colon cancer screening and inves-
tigative technologies have begun to prolif-
erate, one out of every five Americans
with colon cancer has stage IV disease at
the time of their diagnosis.3–5 Many
people with such late stage disease that
has typically metastasised to the liver or
lungs could benefit greatly from palliative
chemotherapy. Synthetic randomised
trial-based evidence has demonstrated its
comforting as well as modest survival-
enhancing effects, but it seems that only
about half of those people with distally
metastasised colon cancer in the USA
ever receive such palliative care.5–7
Our research group has studied colon
cancer care among those who live in
America’s highest poverty neighbour-
hoods where 30–40% or more of the
people have incomes below the poverty
line.8 9 Similar to curative treatment bar-
riers observed among those with non-
metastasised colon cancer and consistent
with this field’s synthetic evidence,4 10–13
we and others have observed significant
barriers to palliative chemotherapy
among people living in poverty with
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metastasised colon cancer.5 14 15 Furthermore, our
analyses found that prevalent health insurance inad-
equacies in America accounted for most, but not all of
the poverty-based chemotherapy inadequacies,
whether the intention was to cure or comfort. Our
premise has been that focusing on the experiences of
the most vulnerable people in the most vulnerable
places magnifies clinical, policy and human
significance.
Barbara Starfield, the late preeminent primary care
researcher and advocate, argued that adequate insur-
ance is necessary, but not sufficient to facilitate access
to high-quality healthcare. She theorised that adequate
primary care also plays a significant facilitating role.16
Studies in the USA have consistently observed protect-
ive associations of primary care physician (PCP) sup-
plies with colon cancer diagnosis, treatment and
survival.10 17 18 Starfield also contended that
increased specialist physician (SP) supplies diminish
public health by increasing the chances that patients
will receive inappropriate or unnecessary specialised
care.19 She centrally theorised that the more specia-
lists, the lower the volume of procedures for each
one, unless the rate of performance of procedures also
increases. So risks of overusing non-indicated thera-
peutic interventions and not performing indicated pal-
liative interventions probably increase with an
increased supply of specialists. This notion of hers
was critiqued on methodological grounds for not con-
trolling for socioeconomic status in cross-sectional
analyses.20 21 In fact, in the field of colon cancer care,
SP effects have been less consistent and have tended
not to fit Starfield’s theory. For example, a Florida
study observed a greater risk of late stage diagnosis in
places that were relatively well supplied overall with
SPs.18 In contrast, our studies in California observed
null to modestly protective association of gastroenter-
ologist supplies with disease stage at diagnosis and sur-
vival.10 17 However, none of these studies focused
specifically on metastasised disease or palliative care,
per se. We are not aware of any longitudinal study
that has examined the independent, income-adjusted
effects of health insurance and physician supplies,
PCPs and specialists, on palliative colon cancer care.
This historical observational study does so.
Recent research found that more than half of all
PCPs provide ongoing care to their patients with
cancer.22 Also, our own clinical experience suggests
that cancer care specialists probably tend to err on the
side of intending to treat for cures. For these reasons,
we think that the palliative care of metastasised colon
cancer probably fits Starfield’s theory well: increased
PCP supplies enhancing access, increased SP supplies
diminishing access. Therefore, our research and prac-
tice experience combined with Starfield’s theory pro-
duced the following hypotheses about the palliative
care of those with metastasised colon cancer. First,
people with adequate health insurance will have better
access to palliative chemotherapy. Second, people
living in places with adequate PCP supplies will also
have better access to such care. And third, people
living in places with ample SP supplies will have
worse access to such care.
Of course, palliative care encompasses a wide range
of interventions and care approaches. We had access
to secondary data that would allow us to explore sur-
gical and chemotherapeutic palliation. This field’s,
above referenced, historical and theoretic contexts,
however, found few socioeconomic gradients and
little managerial or clinical discretion in surgical care.
Thus, we focused on palliative chemotherapy in this
study, where we suspect larger socioeconomic gradi-
ents and much more managerial and clinical
discretion.
METHODS
Study sample
Originally, we randomly sampled 5776 people who
were diagnosed with colon cancer in California
between 1996 and 2000 and followed them to the
present. Moreover, we oversampled those who lived
in poverty. This secondary analysis focused on the
1199 people with stage IV colon cancer that had dis-
tally metastasised at the time of their diagnosis23 and
were followed up for 1 year. The Cancer Registry of
Greater California, anonymised for our analyses, was
the sampling frame. ‘Gold standard’ is one of the
most comprehensive and valid colon cancer registries
in the world.24
The California registry does not collect income
data, so we used patient residential census tracts at the
time of their diagnosis to join it to
neighbourhood-level census data in 2000.25 26
One-third of the original study participants were ran-
domly selected from high poverty neighbourhoods
where 30% or more of the people were poor, that is,
they had household incomes below the federally
established poverty criterion.8 9 Four of every 100
Californians live in such high poverty neighbour-
hoods.25 The remaining participants were randomly
selected from lower poverty neighbourhoods (<30%
poor).
Health insurance and physician supply measures
Health insurance data were collected from hospital
records by cancer registrars. Primary health insurers
were defined as private (these included
Medicare-insured with private supplemental cover-
age), public (Medicare alone or Medicaid) or none.
Our previously referenced research has consistently
found public health insurance, Medicaid or Medicare,
and of course having no such insurance, to be rela-
tively inadequate when compared with more adequate
private health insurance. We then identified communi-
ties with relatively low to high healthcare
Research
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endowments, characterised by physician supplies. To
do this, we joined participants to county-level active,
full-time equivalent, physician data via the American
Medical Association’s database in 2000.27 PCPs were
those who reported their speciality area as general or
family practice. Physicians reporting the majority of
their time spent in specialised practice or were board
certified in that speciality were so defined.28
Threshold effects, below which the study sample was
less likely to receive palliative chemotherapy, were
identified by exploring 0.5 physician increments:
PCPs and aggregate SPs per 10 000, and gastroenter-
ologists, general surgeons and oncologists, medical or
surgical, per 100 000 community inhabitants.
Analysis
Tumours were prevalently high grade. Only 6% were
well differentiated. Most people with such late stage-
high grade tumours could probably benefit from che-
motherapeutic palliation. This characteristic did not
confound any analysis, so it was not entered into any
standardisation or regression. We directly and intern-
ally adjusted chemotherapy rates using a standard
population with the age characteristics of this study’s
sample. Such adjustments were made across these age
categories: 25–59, 60–69, 70–79 and 80 or older.
The standard was used to calculate comparable
age-standardised rates for respective adequately and
inadequately insured and supplied subsamples. All
rates were calculated per 100 participants and
reported as percentages. We used standardised rate
ratios (RR) for between-group comparisons with 95%
CIs derived from the χ2 test. The original analysis was
specifically powered to detect small therapeutic rate
differences. The available sample of 1199 for this sec-
ondary analysis of palliative chemotherapy allowed
for confident detection of rate differences as small as
5% (two-tailed α=0.05; power1–β=0.80).
29
We then used logistic regression models to test
hypotheses.30 We estimated the strength of each
predictor-palliative chemotherapy relationship adjust-
ing for the effects of other predictors as well as for
the potentially confounding influences of age and
poverty. ORs and 95% CIs were estimated from
regression statistics. The criterion variable of palliative
chemotherapy receipt seemed to have additional clin-
ical validity as those who received it were also twice
as likely to survive for 1 year.
RESULTS
The effects of health insurance and physician supplies,
primary care and specialists, are described in table 1.
First, being adequately insured by a commercial or
private insurance company was associated with a 14%
increase in the receipt of palliative chemotherapy
(RR=1.14, 95% CI 1.00 to 1.30). Chemotherapy
rates among the uninsured or Medicaid or
Medicare-insured did not differ significantly from
each other. Second, living in a community that was
adequately supplied with 8.5 or more PCPs per
10 000 inhabitants substantially increased one’s
chances of receiving chemotherapy by 23%
(RR=1.23, 95% CI 1.00 to 1.51). Such adequately
PCP-supplied communities were also associated with
substantially decreased chances of waiting longer than
2 months to receive chemotherapy (19% vs 31%,
RR=0.61, 95% CI 0.47 to 0.80, data not shown).
And third, living in a community that was very well
supplied with 16 or more SPs per 10 000 inhabitants
decreased one’s chances of receiving chemotherapy by
14% (RR=0.86, 95% CI 0.75 to 0.98). Furthermore,
the effects of specific specialists all followed this
pattern, though they ranged from significant (oncolo-
gists) to non-significant trends (general surgeons). The
effect of gastroenterologists approached statistical sig-
nificance (RR=0.86, 90% CI 0.75 to 0.99). All
effects were hypothetically consistent. Despite such
facilitation by primary care and health insurance, it
should be noted that the chemotherapy rate for the
sample as a whole was only 45%.
As an aside, we also explored these effects on the
receipt of palliative surgery, and found that only those
with any health insurance (73%) were much more
likely than the uninsured (45%) to receive such
surgery (RR=1.62, 95% CI 1.37 to 1.92). Surgery
rates among the privately or Medicare or
Medicaid-insured did not differ significantly from
each other. Neither PCP nor SP supplies affected
surgery rates.
Table 1 Effects of health insurance and physician supplies on
palliative chemotherapy for 1199 people with metastasised colon
cancer
Baseline
Observed group Sample
Chemotherapy
rate (%)
Rate
ratio 95% CI
Uninsured or publicly
insured
662 40.3
Privately insured 537 45.9 1.14* 1.00 to 1.30
<8.5 primary care
physicians†
1083 42.8
≥8.5 primary care
physicians†
116 52.6 1.23* 1.00 to 1.51
<16 specialist physicians† 512 47.4
≥16 specialist
physicians†
687 41.0 0.86* 0.75 to 0.98
<2 gastroenterologists‡ 174 50.7
≥2 gastroenterologists‡ 1025 43.5 0.86 0.73 to 1.02§
<7 general surgeons‡ 117 48.7
≥ 7 general surgeons‡ 1082 44.0 0.90 0.73 to 1.11
<3 oncologists‡ 550 48.6
≥3 oncologists‡ 649 41.1 0.85* 0.75 to 0.96
*p<0.05.
†Physician densities per 10 000 community inhabitants.
‡Physician densities per 100 000 community inhabitants.
§90% CI 0.75 to 0.99, p<0.10.
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Two logistic regression models that tested predictors
of palliative chemotherapy are displayed in table 2.
Model 1 that was not adjusted for poverty essentially
replicated the previously described protective effects
of primary care and health insurance as well as the
seemingly harmful effect of specialised care. Model 2
that was poverty-adjusted suggested the precedence of
primary care in predicting access to palliative chemo-
therapy for those with metastasised colon cancer. The
still statistically significant effect of PCP supply was
quite large (OR=1.60, 95% CI 1.02 to 2.56), but the
size of the health insurance and SP effects were atte-
nuated and/or no longer statistically significant.
DISCUSSION
Palliative chemotherapy was received by less than half
of this historical California cohort’s participants with
metastasised colon cancer. As hypothesised, significant
facilitating effects of primary care and health insur-
ance as well as an impeding effect of specialised care
were observed. Primary care seemed to take prece-
dence. Controlling for poverty, PCP supply was the
only predictor of chemotherapy receipt that remained
statistically significant and practically strong. Adequate
primary care was also protectively associated with
much shorter waits for palliative chemotherapy. The
threshold for these primary care effects was quite high
though, only being realised in quite amply supplied
communities with 8.5 or more PCPs per 10 000 inha-
bitants. Only 10% of this study’s participants lived in
such very well-supplied communities.
This study’s central findings on palliative chemo-
therapy were consistent with those of another recent
study of people with non-metastasised colon cancer
treated with the intent to cure.10 Among California
and Ontario samples, a less stringent PCP supply
threshold of 7.5 or more PCPs for every 10 000 com-
munity inhabitants was protectively associated with
10-year survival. Consistent with Starfield’s further
theorising about the benefits of Canada’s stronger
primary care orientation,31 the protective
PCP-survival association was stronger in Ontario than
California. Moreover, among that study’s sample of
people with non-metastasised colon cancer, 4 of every
10 in Ontario, but only 1 of every 10 in California
lived in such adequately supplied communities.10 We
had access to a contemporaneous sample of people
with metastasised colon cancer in Ontario, but unfor-
tunately, it was too small to provide statistically
powerful and so confident comparisons. It does,
however, suggest again that Canadians are much more
likely to live in communities that are very well sup-
plied with PCPs. For example, 3 of every 10 such
Ontarians (unpublished data) compared with this
study’s estimate of only 1 of every 10 Californians
lived in communities that were very well supplied
with 8.5 or more PCPs for every 10 000 inhabitants.
Therefore, one would expect much better access to
palliative chemotherapy for metastasised colon cancer
in Ontario. These Ontario data also suggest that
oncologist supplies (3 or more per 100 000 commu-
nity inhabitants) may facilitate, rather than impede,
access to palliative chemotherapy in Ontario
(RR=1.33, 90% CI 1.02 to 1.73, unpublished data).
Provocative international comparisons remain for
future research testing with ample, prospective
cohorts. Clinical and policy decision makers in the
USA may have much to learn about primary care as
well as primary-specialist care collaborations in pallia-
tive care from their Canadian neighbours.
Potential limitations
Our findings may not be generalisable to all
Americans. However, because 1 in 10 Americans lives
in California, we think they have ample external vali-
dity.32 Admittedly, in that we purposefully over-
sampled those who lived in poverty, this study’s
findings are most representative of their experiences.
Furthermore, California’s expanded Medicaid pro-
gramme is more liberal than most states’, so estimates
of healthcare inequities among the poor or near poor
there are probably underestimates of the nation’s.33–35
Next, because chemotherapy is most often received as
an outpatient, it can be challenging for cancer regis-
tries to survey. However, the Cancer Registry of
Greater California was nearly complete on chemother-
apy at the time of this analysis.36 And any modest
errors probably did not differ by socioeconomic
factors such as income or health insurance37 so were
very unlikely to have confounded this study’s analyses.
This study was also limited by the fact that its
Table 2 Logistic regression of health insurance and physician
density on the receipt of palliative chemotherapy for 1199 people
metastasised colon cancer
Predictor variables OR 95% CI
Model 1: age-adjusted
Privately insured 1.34* 1.03 to 1.74
≥8.5 primary care physicians/10 000 community
inhabitants
1.61* 1.05 to 2.47
≥16 specialist physicians/10 000 community
inhabitants
0.63* 0.49 to 0.81
Model 2: Age and poverty-adjusted
Privately insured 1.21 0.97 to 1.52
≥8.5 general practitioners/10 000 community
inhabitants
1.62* 1.02 to 2.56
≥16 specialist physicians/10 000 community
inhabitants
0.74 0.50 to 1.02
All effects were adjusted for age (25–59 (25%), 60–60 (24%), 70–79
(28%) and 80 years or older (23%)) and all other effects in each model.
Model 2 was further adjusted for living in a high poverty neighbourhood
(33%). Total physician supply did not enter either model after primary care
and specialist physician supplies entered. Gender (50% each women and
men) did not enter either model nor did it interact with any other effect,
so this pattern is likely the same for women and men.
*p<0.05.
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physician supply measures were county-level aggregates
and so did not directly examine individual physician
behaviours and physician–patient relationships. Instead,
they were conceived as proxies of community-level
phenomena, that is, of healthcare service endowments.
Therefore, we think that population-level policy-
relevant inferences can be most appropriately drawn
from this study. Future research, observational and
qualitative, will be needed to sort out the relative clin-
ical importance of various PCP behaviours, for
example: provision of initial information, active refer-
ral, liaison with oncologists and other specialists,
advocacy for palliative care, prevention or manage-
ment of adverse palliation effects, care coordination
and ongoing surveillance. Relatedly, we were not able
to measure patient behaviours. Those of most interest,
of course, would be those related to their quality of
life, social supports and preferences.38–40 Future
studies ought to include such individual-level patient
measures as well.
It could also be argued that referral to palliative
chemotherapy may not have been appropriate for all
such patients. But our practice experience suggests
that most people, like this study’s participants with
late stage-high grade tumours, could probably benefit
from chemotherapeutic palliation. In fact, there
seemed to have been few cases where referral to pal-
liative chemotherapy was not appropriate. Medical
records indicated that such care was contraindicated
in <1% and refused in <5% of the cases. These few
cases were unlikely to have confounded our analysis
as we controlled for their probable key predictors:
age, stage and grade through mathematical modelling
(logistic regression) and sample restriction. Finally, we
studied metastasised colon cancer because we sus-
pected it was a sentinel palliative care indicator, but
there probably are many others. Presently, we are
designing a systematic replication among women with
certain forms of breast cancer that are generally not
amenable to treatment for cures. We invite other
teams of clinicians and researchers to replicate and
extend these findings across other diagnostic, includ-
ing non-cancer, groups in need of high-quality pallia-
tive care.
CONCLUSIONS
This historical study’s observations of the facilitating
effects of primary care and health insurance on pallia-
tive chemotherapy for metastasised colon cancer prior
to enactment of the Affordable Care Act (ACA)
clearly suggested a way to maximise ACA protections.
Notwithstanding the importance of adequately insur-
ing all, strengthening America’s system of primary
care will probably be the best way to ensure that the
ACA’s full benefits are realised. Such would go a long
way towards facilitating access to palliative care.
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